Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Increase in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 241,900 shares, a growth of 350.5% from the October 15th total of 53,700 shares. Based on an average trading volume of 268,900 shares, the short-interest ratio is presently 0.9 days. Currently, 0.4% of the company’s stock are sold short.

Tiziana Life Sciences Trading Down 3.2 %

TLSA stock traded down $0.03 on Wednesday, hitting $0.91. The company had a trading volume of 21,538 shares, compared to its average volume of 208,609. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.74. The stock’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $0.93.

Institutional Investors Weigh In On Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,387 shares of the company’s stock after purchasing an additional 13,500 shares during the quarter. Zhang Financial LLC owned 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent quarter.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.